country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-151949

Copy Link Print Information

TrkA-IN-4

Kundenbewertung

Based on 1 Customer Validation

TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC₅₀=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.99%
CAS. Nr.: 3026111-74-7
Formel: C₂₇H₂₁F₃N₄O₅
Molecular Weight:538.47

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

TrkA-IN-4 Chemical Structure

CAS. Nr.: 3026111-74-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC₅₀=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects^[1].

IC₅₀ & Target^[1]

TrkA

Alle Trk Receptor Isoform-spezifische Produkte anzeigen :

In Vitro

TrkA-IN-4 (compound 39) demonstrates 65.1% and 46.3% of kinase inhibition towards TrkA at concentrations of 1 μM and 0.1 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TrkA-IN-4 (compound 39) (0.9375-120 mg/kg; i.g.) exhibits stronger maximum antinociceptive effects 3 h after administration, with an ED₅₀ of 7.836 mg/kg in hot plate testing on male mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KM male mice (20-24 g) were received hot plate test
Dosage:

0.9375, 1.875, 3.75, 7.5, 15, 30, 60, 120 mg/kg
Administration:

A single i.g.
Result:

3 h after administration, exhibited potent antinociceptive effects, with an ED₅₀ of 7.836 mg/kg.

Chemical Information

CAS. Nr. 3026111-74-7
Appearance Solid
Molecular Weight 538.47
Formel C₂₇H₂₁F₃N₄O₅
Color White to off-white
SMILES

CC(OCOC(C1=CN=C(C(NC(C2=CC=C(C(C3=NN(C=C3)C)=C2)C(F)(F)F)=O)=C1)C4=CC=CC=C4)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (92.86 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8571 mL

9.2856 mL

18.5711 mL

5 mM

0.3714 mL

1.8571 mL

3.7142 mL

10 mM

0.1857 mL

0.9286 mL

1.8571 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8571 mL	9.2856 mL	18.5711 mL	46.4278 mL
	5 mM	0.3714 mL	1.8571 mL	3.7142 mL	9.2856 mL
	10 mM	0.1857 mL	0.9286 mL	1.8571 mL	4.6428 mL
	15 mM	0.1238 mL	0.6190 mL	1.2381 mL	3.0952 mL
	20 mM	0.0929 mL	0.4643 mL	0.9286 mL	2.3214 mL
	25 mM	0.0743 mL	0.3714 mL	0.7428 mL	1.8571 mL
	30 mM	0.0619 mL	0.3095 mL	0.6190 mL	1.5476 mL
	40 mM	0.0464 mL	0.2321 mL	0.4643 mL	1.1607 mL
	50 mM	0.0371 mL	0.1857 mL	0.3714 mL	0.9286 mL
	60 mM	0.0310 mL	0.1548 mL	0.3095 mL	0.7738 mL
	80 mM	0.0232 mL	0.1161 mL	0.2321 mL	0.5803 mL

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

TrkA-IN-4

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Alle Trk Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

TrkA-IN-4

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Alle Trk Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

TrkA-IN-4 Related Classifications

HY-151949 Related Classifications